A five-year review of prevalence and treatment outcomes of pre-extensively drug-resistant plus additional drug-resistant tuberculosis in the Henan Provincial Tuberculosis Clinical Medicine Research Centre

医学 吡嗪酰胺 肺结核 广泛耐药结核 利奈唑啉 内科学 结核分枝杆菌 抗药性 养生 药品 异烟肼 基岩 药理学 微生物学 病理 万古霉素 生物 细菌 遗传学 金黄色葡萄球菌
作者
Wei Wang,Fuyong Liu,Huihui Chen,Yun-gang Han,Yonghe You,Yongsheng Xie,Yue Zhao,Jiao Tan,Xu Guo,Yuntao Cheng,Yali Wang,Jing Li,Meijin Cheng,Shuang Xia,Xiaodong Niu,Lukuan Wei,Wei-Bung Wang
标识
DOI:10.1016/j.jgar.2022.09.010
摘要

This study investigated the prevalence and significant clinical outcomes of pre-extensively drug-resistant plus additional drug-resistant tuberculosis (pre-XDR-plus) in Henan Provincial Chest Hospital between 2017 and 2021. We analysed and summarized the drug sensitivity test (DST) results of clinical Mycobacterium tuberculosis (MTB) strains in TB patients seeking care in the Tuberculosis Clinical Medical Research Centre of Henan Province between 2017 and 2021. Medical records of pre-extensively drug-resistant plus additional drug-resistant TB patients were statistically analysed, including demographic characteristics, regimens, and outcomes. Of the 3689 Mycobacterium tuberculosis strains, 639 (17.32%), 353 (9.56%), and 109 (2.95%), multidrug-resistant tuberculosis (MDR-TB), pre-extensively drug-resistant tuberculosis (pre-XDR), and pre-XDR-plus, respectively. The proportion of MDR decreased from 19.1% in 2017 to 17.5% in 2021 (χ2 = 0.686, P = 0.407), the proportion of pre-XDR from 11.4% in 2017 to 9.0% in 2021 (χ2 = 2.39, P = 0.122), and pre-XDR-plus from 4.7% in 2017 to 1.8% in 2020, with the declining trend was significant (χ2 = 9.348, P = 0.002). The most commonly used anti-TB drugs were pyrazinamide (PZA, 37/46, 80.43%) and cycloserine (CS, 32/46, 69.57%), followed by linezolid (LZD, 25/46, 54.35%), protionamide (TH, 25/46, 54.35%), and para-aminosalicylic acid (PAS, 23/46, 50.00%). Patients receiving the LZD regimen were 5 times more likely to have a favourable outcome than those not receiving LZD (OR = 6.421, 95% CI 2.101–19.625, P = 0.001). Patients receiving a regimen containing CS were 4 times more likely to have a favourable outcome compared to those not taking CS (OR = 5.444, 95% CI 1.650–17.926, P = 0.005). Our data suggest that the population of pre-XDR-plus had significantly decreased over the past five years in the Henan Provincial Chest Hospital. The COVID-19 and flood disaster affect TB patients’ selection of medical services. In addition, the pre-XDR-plus patients whose regimens contain LZD or CS were more likely to have favourable outcomes.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ziyingxia发布了新的文献求助10
刚刚
1秒前
DD完成签到 ,获得积分10
1秒前
1秒前
XX发布了新的文献求助10
2秒前
3秒前
3秒前
4秒前
chan完成签到,获得积分10
4秒前
4秒前
我要发Natrue完成签到,获得积分10
4秒前
jianinghehe完成签到,获得积分10
6秒前
6秒前
今后应助绝迹天明采纳,获得10
6秒前
小二郎应助友好广缘采纳,获得10
6秒前
7秒前
Mottri完成签到,获得积分10
7秒前
8秒前
hkl1542发布了新的文献求助10
8秒前
豆子关注了科研通微信公众号
9秒前
科研小白完成签到,获得积分10
10秒前
10秒前
秀丽茹妖发布了新的文献求助10
10秒前
Hello应助司康采纳,获得10
11秒前
知行合一发布了新的文献求助10
11秒前
12秒前
12秒前
13秒前
Two-Capitals发布了新的文献求助10
13秒前
ruanyousong发布了新的文献求助30
13秒前
15秒前
ziyingxia完成签到,获得积分20
15秒前
上官若男应助疯狂的听双采纳,获得10
15秒前
虚心的小兔子完成签到,获得积分10
15秒前
16秒前
我是老大应助辛勤的晓兰采纳,获得10
16秒前
16秒前
李cx发布了新的文献求助10
17秒前
18秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Kinesiophobia : a new view of chronic pain behavior 3000
Les Mantodea de guyane 2500
Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics 2000
What is the Future of Psychotherapy in a Digital Age? 700
The Psychological Quest for Meaning 600
Zeolites: From Fundamentals to Emerging Applications 600
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5955172
求助须知:如何正确求助?哪些是违规求助? 7165292
关于积分的说明 15937270
捐赠科研通 5090001
什么是DOI,文献DOI怎么找? 2735504
邀请新用户注册赠送积分活动 1696337
关于科研通互助平台的介绍 1617268